BioCryst Pharmaceuticals | BCRX - 市值



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.71B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


市值 更改 日
Alnylam Pharmaceuticals USD 44.15B 8.39B 2026-03
BioCryst Pharmaceuticals USD 1.66B 64M 2025-12
Chugai Pharma JPY 14.46T 617.89B 2026-03
Daiichi Sankyo JPY 6.34T 62.51B 2025-12
DBV Technologies USD 274M 17M 2025-09
Enanta Pharmaceuticals USD 122M 98M 2024-12
Gilead Sciences USD 167.39B 5.6B 2026-05
GlaxoSmithKline GBP 83.8B 9.44B 2026-03
Incyte USD 21.73B 3B 2026-05
Ionis Pharmaceuticals USD 12.46B 356M 2026-03
Karyopharm Therapeutics USD 956M 821M 2026-05
Neurocrine Biosciences USD 15.15B 1.9B 2026-05
Novavax USD 1.09B 316M 2025-12
PTC Therapeutics USD 4.94B 698M 2026-05
Regeneron Pharmaceuticals USD 81.68B 560M 2026-03
Roche Holding CHF 266.34B 55.46B 2025-12
Sarepta Therapeutics USD 2.16B 123M 2026-05
Ultragenyx Pharmaceutical USD 2.06B 1000K 2026-05
Vertex Pharmaceuticals USD 113.58B 1000K 2026-05